Skip to main content

REVIEW article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1424569
This article is part of the Research Topic The Molecular Mechanisms and Therapeutic Implications of Protein Kinase Inhibitors in Cancer Therapy View all articles

Biological Functions and Therapeutic Potential of CKS2 in human cancer

Provisionally accepted
Yueliang Lai Yueliang Lai 1*Ye Lin Ye Lin 1,2
  • 1 Ganzhou People's Hospital, Ganzhou, China
  • 2 Department of Gastroenterology, Ganzhou People’s Hospital, ganzhou, China

The final, formatted version of the article will be published soon.

    The incidence of cancer is increasing worldwide and is the most common cause of death. Identification of novel cancer diagnostic and prognostic biomarkers is important for developing cancer treatment strategies and reducing mortality. Cyclin-dependent kinase subunit 2 (CKS2) is involved in cell cycle and proliferation processes, and based on these processes, CKS2 was identified as a cancer gene. CKS2 is expressed in a variety of tissues in the human body, but its abnormal expression is associated with cancer in a variety of systems. CKS2 is generally elevated in cancer, plays a role in almost all aspects of cancer biology (such as cell proliferation, invasion, metastasis, and drug resistance) through multiple mechanisms regulating certain important genes, and is associated with clinicopathological features of patients. In addition, CKS2 expression patterns are closely related to cancer type, stage and other clinical variables. Therefore, CKS2 is considered as a tool for cancer diagnosis and prognosis and may be a promising tumor biomarker and therapeutic target. This article reviews the biological function, mechanism of action and potential clinical significance of CKS2 in cancer, in order to provide a new theoretical basis for clinical molecular diagnosis, molecular targeted therapy and scientific research of cancer.

    Keywords: Cyclin-dependent kinase subunit 2 (CKS2), Cancer, biomarker, oncogene, targeted therapy

    Received: 28 Apr 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Lai and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yueliang Lai, Ganzhou People's Hospital, Ganzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.